UB Paderborn / Katalog / Suche / in CDI

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281-289

2019

Volltextzugriff (PDF)

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of oncology, 2016-07, Vol.27 (7), p.1291-1298

2016

Volltextzugriff (PDF)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Annals of oncology, 2017-06, Vol.28 (6), p.1388-1398

2017

Volltextzugriff (PDF)

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

Annals of oncology, 2018-10, Vol.29, p.viii749-viii749

2018

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Volltextzugriff (PDF)

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S216-S217

2019

Volltextzugriff (PDF)

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Annals of oncology, 2016-10, Vol.27, p.vi578-vi578

2016

Volltextzugriff (PDF)

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.S152-S152

2018

Volltextzugriff (PDF)

LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion

Annals of oncology, 1998-01, Vol.9 (1), p.101-104

1998

Volltextzugriff (PDF)

LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S391-S391

2018

Volltextzugriff (PDF)

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S216-S216

2019

Volltextzugriff (PDF)

Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

Annals of oncology, 2016-10, Vol.27, p.vi422-vi422

2016

Volltextzugriff (PDF)

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50

Annals of oncology, 2016-12, Vol.27, p.ix139-ix139

2016

Volltextzugriff (PDF)

Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7028-7028

2011

Volltextzugriff (PDF)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281

2019

Volltextzugriff (PDF)

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16020-16020

2008

Volltextzugriff (PDF)

Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4768-4768

2004

Volltextzugriff (PDF)

Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4768-4768

2004

Volltextzugriff (PDF)

Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma results of a meta-analysis

Cancer, 2004-12, Vol.101 (12), p.2755-2759

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1

LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion

LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50

Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations

Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations

Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma results of a meta-analysis

Suchergebnisse filtern